Theravance Biopharma Reports Record 2024 Financial Results

Theravance Biopharma ( (TBPH) ) has released its Q4 earnings. Here is a breakdown of the information Theravance Biopharma presented to its investors.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases and other serious conditions, with a notable product being YUPELRI, a long-acting muscarinic antagonist for COPD patients.

In its latest earnings report, Theravance Biopharma announced record financial results for the fourth quarter and full year 2024, driven by strong sales of YUPELRI and significant milestone achievements related to TRELEGY sales. The company also highlighted progress in its clinical development programs and strategic initiatives.

Key financial highlights include YUPELRI US net sales reaching $66.7 million in Q4 and $238.6 million for the full year, marking increases of 10% and 8% respectively compared to 2023. Additionally, TRELEGY’s global net sales reported by GSK rose by 26% to $3.46 billion, triggering a $50 million milestone payment to Theravance. The company ended the year with $88 million in cash, excluding the milestone payment, and reported a net loss of $15.5 million for Q4.

Strategically, Theravance is advancing its CYPRESS study for ampreloxetine, a potential treatment for neurogenic orthostatic hypotension, with plans for an expedited NDA filing following study completion. The company is also conducting a strategic review to explore options for enhancing shareholder value.

Looking ahead, Theravance Biopharma remains focused on driving growth through its commercial and clinical development efforts, with expectations of continued sales momentum for YUPELRI and potential future milestones from TRELEGY. The company aims to maintain minimal non-GAAP losses and cash burn levels in 2025, while pursuing strategic opportunities to maximize shareholder returns.